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imatinib mesylate and omacetaxine
mepesuccinate toxicity in lymphoblastoid
cell lines
Hemant Kulkarni1*, Harald H H Göring1, Vincent Diego1, Shelley Cole1, Ken R Walder2, Greg R Collier3,
John Blangero1 and Melanie A Carless1*Abstract
Background: Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient
resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity.
Given that drug cytotoxicity represents a major problem during treatment, it is essential to understand the
biological pathways affected to better predict poor drug response and prioritize a treatment regime.
Methods: We conducted cell viability and gene expression assays to determine heritability and gene expression
changes associated with imatinib and omacetaxine treatment of 55 non-cancerous lymphoblastoid cell lines,
derived from 17 pedigrees. In total, 48,803 transcripts derived from Illumina Human WG-6 BeadChips were analyzed
for each sample using SOLAR, whilst correcting for kinship structure.
Results: Cytotoxicity within cell lines was highly heritable following imatinib treatment (h2 = 0.60-0.73), but not
omacetaxine treatment. Cell lines treated with an IC20 dose of imatinib or omacetaxine showed differential gene
expression for 956 (1.96%) and 3,892 transcripts (7.97%), respectively; 395 of these (0.8%) were significantly
influenced by both imatinib and omacetaxine treatment. k-means clustering and DAVID functional annotation
showed expression changes in genes related to kinase binding and vacuole-related functions following imatinib
treatment, whilst expression changes in genes related to cell division and apoptosis were evident following
treatment with omacetaxine. The enrichment scores for these ontologies were very high (mostly >10).
Conclusions: Induction of gene expression changes related to different pathways following imatinib and
omacetaxine treatment suggests that the cytotoxicity of such drugs may be differentially tolerated by individuals
based on their genetic background.
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Chronic myeloid leukemia (CML) represents a myeloproli-
ferative condition characterized by a t(9;22)(q34;q11) trans-
location that forms the BCR-ABL1 fusion gene [1]. The
chimeric protein end-product of this gene has a dysregulated
tyrosine kinase activity, which leads to disruption of several
vital cellular pathways, including failure of proper apoptotic
mechanisms [2,3]. The last decade has seen remarkable
improvements in the treatment of CML, largely due to tyro-
sine kinase inhibitors like imatinib mesylate, which have now
become the mainstays of CML therapy. In spite of highly en-
couraging reports of the protection and survival advantage
conferred by imatinib treatment, [4-6] it is becoming increas-
ingly recognized that a substantial proportion of patients ac-
quire resistance to it (2-year incidence of resistance is ~80% in
the blast phase, 40-50% in accelerated phase and 10% in the
chronic phase) [7] and therefore secondary lines of treatment
are essential [8]. One of the commonly used drugs in imatinib
resistant cases is omacetaxine mepesuccinate, which acts by
disrupting protein synthesis, degrading myeloid leukemia cell
differentiation protein (MCL-1) and inducing apoptosis
[9-12]. While there is a regained and renewed interest in the
potential use of omacetaxine in imatinib-resistant CML cases,
[1,13] full recognition of its potential is far from established.
In addition to resistance, it has been found that 3-8% of
imatinib-treated subjects discontinue treatment because of
the cytotoxic effects of the drug [14,15]. While the apoptotic
effect of omacetaxine is known, emerging evidence suggests
that imatinib can also induce cytotoxicity via apoptosis
within BCR-ABL1 negative cancers through several mechan-
isms, including: inhibition of DNA topoisomerases [16];
increased expression of Spred2 [17]; induction of autophagy
[18,19]; and induction of complement dependent pathways
[20], or Bim and Bad proteins [21,22]. However, the
driving molecular mechanisms involved in imatinib- and
omacetaxine-induced cytotoxicity remain largely unknown.
We therefore conducted a systematic evaluation of cyto-
toxicity in imatinib- and omacetaxine-treated cells. In this
study we tested two hypotheses. First, we conjectured that
the concentration of imatinib or omacetaxine needed to in-
hibit growth of non-cancerous lymphoblastoid cell lines is a
heritable trait. Second, we hypothesized that inhibition of
cells by these drugs ensues quantifiable and characteristic
changes in gene expression. Using lymphoblastoid cell lines
derived from pedigreed individuals, [23] we determined the
heritability of inhibitory concentrations (IC20) of both imati-
nib mesylate and omacetaxine mepesuccinate and identified
gene expression changes associated with drug cytotoxicity.117; 216 test well abs570nmð Þ  80; 586 testð
117; 216 untreated well abs570nmð Þ  80; 586 untðMethods
Cell lines and drugs
Cell lines were derived from Epstein-Barr virus-immor-
talized lymphoblastoid cells of pedigreed individuals par-
ticipating in the San Antonio Family Heart Study [23].
All cell lines were maintained in RPMI 1640 medium
containing 2 mM L-glutamine, 1X antibiotic/antimyco-
tic, 1 mM sodium pyruvate, 1X non-essential amino
acids, 10 mM HEPES and 15% FBS (Invitrogen, Carls-
bad, CA) at 37°C and 5% CO2. In total, 109 cell lines
were assessed for imatinib mesylate cell viability and
113 cell lines were tested for omacetaxine mepesucci-
nate cell viability, obtained from 17 pedigrees (ranging
in size from 6 to 10 individuals). Of these, 55 cell lines
were further assessed for genome-wide gene expres-
sion changes in response to imatinib and omacetaxine
treatment and for sensitivity of drug response studies.
Cell lines were chosen based on familial relationships,
allowing heritability of cell viability to be determined.
Imatinib mesylate (LKT Laboratories, St Paul, MN)
and omacetaxine mepesuccinate (ChemGenex, Melbourne,
Australia) were solubilized in water at 10 mM and 10 μM
concentrations, respectively, and stored at −20°C until used
in experiments. Stock solutions were further diluted in
water and then media for all assays.
Cell viability studies
Cell viability assays were carried out in a similar manner to
previous studies [24]. Cells were initially grown in 75 cm2
flasks, harvested and plated in triplicate into a 96 well
clear-bottom plate at a density of 1×105cells/ml, 180 μl per
well. Cells were grown for 24 hrs and then treated with
varying concentrations of either imatinib mesylate or oma-
cetaxine mepesuccinate drug (in 20 μl volume) for 72 hrs
before the addition of 20 μl alamarBlue reagent (Life Tech-
nologies, Grand Island, NY). Imatinib was added at con-
centrations of 2 μM, 10 μM, 50 μM, 75 μM, 100 μM,
150 μM and 200 μM and omacetaxine was added at con-
centrations of 5nM, 10nM, 25nM, 50nM, 75nM, 100nM
and 500nM. Following the addition of alamarBlue, cells
were incubated for a further 24 hours and fluorescence
read at 570 nm and 600 nm using the SpectraMax 340PC
384 micro plate reader (Molecular Devices, Sunnyvale,
CA). Absorbance readings for the triplicate reactions were
averaged to calculate percent reduction. To calculate the
percent difference in reduction of the alamarBlue reagent
between treated and control cells (cell viability), the follow-
ing equation was used:well abs600nmÞ
reated well abs600nmÞ  100 ð1Þ
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marBlue in its oxidized form at 600 nm; 80,586 is the
molar extinction coefficient of alamarBlue in its oxidized
form at 570 nm; and abs indicates the absorbance. Graph-
Pad PRISM v5 software was used to plot dose response
curves and determine IC20 values for both imatinib and
omacetaxine for each cell line.
Gene expression assays
Each of the 55 selected cell lines was treated with either
imatinib, omacetaxine or was left untreated. Each cell
line was treated for 96 hours with a concentration of
drug equivalent to the IC20 value (calculated for each
cell line individually); additional media containing the
appropriate concentration of drug was added after the
first 48 hours. A concentration equivalent to IC20 was
utilized for two reasons: i) we aimed at maintaining the
viability of the majority of cells to make reliable esti-
mates of the gene expression profiles; and ii) previously
published drug toxicity studies have used this cut-off in
toxicological gene expression studies [25-28]. Following
drug treatment, cells were collected by centrifugation at
3,000 g for 5 minutes and RNA was extracted using the
RNeasy Mini Kit (Qiagen, Valencia, CA), according to
the manufacturers’ instructions. RNA concentration was
determined using the NanoDrop ND-1000 (Thermo-
Scientific, Wilmington, DE) and integrity was assessed
using the Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA). All samples were of high quality, having
RNA integrity numbers (RIN) > 9.0. Anti-sense RNA
(aRNA) was synthesized, amplified and purified from
500 ng total RNA following manufacturers’ guidelines
for the Ambion MessageAmp II-Biotin Enhanced Single
Round aRNA Amplification kit (Life Technologies).
A total of 1.5 μg aRNA was hybridized to Illumina
Human WG-6 v3 BeadChips according to manufac-
turers’ instructions and scanned using the IlluminaW
BeadArray™ 500GX Reader with IlluminaW BeadScan
image data acquisition software (version 2.3.0.13). To as-
sess quality metrics of each run, several quality control
procedures were implemented, including a total RNA
control sample and assessment of control summary
reports, which allows the user to look for variations in
signal intensity, hybridization signal, background signal
and the background-to-noise ratio for all samples ana-
lyzed. IlluminaW BeadStudio software (version 1.5.0.34)
was used for preliminary data analysis, with a standard
background subtraction, to generate an output file for
statistical analysis.
Statistical analysis
Analyses were conducted on two sets of experimental
results. Using data from Experimental Series 1 (Figure 1),
we first obtained the log fold changes (differential geneexpression) in response to imatinib and omacetaxine
treatment (iFC and oFC, respectively). Raw signal inten-
sity data generated in BeadStudio was normalized using
quantile normalization (see Additional file 1) as described
elsewhere [29]. For each probe, we then tested whether
differential gene expression significantly deviated from
zero using a paired Student’s t test. As the dataset origi-
nated from related individuals, and to correct for the con-
sequent within-family correlations and potential kinship
effects, we tested the significance of iFC and oFC using a
sporadic model of the following form:
FC ¼ mþ βaþ ei ð2Þ
where FC is fold change in response to a drug, m is aver-
age fold change attributable to the drug treatment after
accounting for kinship and covariates, β is the regression
coefficient vector corresponding to the covariate matrix a
and ei is the measurement error. The covariates used in all
models were age, sex, age × sex interaction, age2 and
age2 × sex interaction. The statistical significance of m was
tested by constraining it to zero and estimating χ2(degree
of freedom=1) as twice the difference between the log-
likelihood from un-constrained and constrained models.
We then used the Benjamini-Hochberg method to correct
for multiple comparisons based on false discovery rates.
For this we used the qqvalue.ado software [30] in Stata en-
vironment. Results of these analyses were depicted as vol-
cano plots. Lastly, we used the k-means clustering method
to group the significantly differentially expressed genes
(using Euclidean distance) based on the mean iFC and
oFC values estimated using Equation (1).
Using data from Experimental Series 2 (Figure 1), we
estimated for each probe the contribution of differential
gene expression to the sensitivity of drug response
(SDR), a measure of how sensitive a cell line is to
changes in cell viability based on drug concentration.
Sensitivity of imatinib (iSDR) and omacetaxine (oSDR)
response was defined as the slope of the fitted linear re-
gression lines that used log of dose as the independent
variable and cell viability as the dependent variable. To
account for within-family correlations, kinship structure
and the potential heritability of SDR, we ran a polygenic
model for each probe as follows:
SDR ¼ μþ βaþ gi þ ei ð3Þ
where, SDR is the sensitivity of drug response, μ is the
overall mean SDR, β is the regression coefficient vector
corresponding to the covariate matrix a, gi is the poly-
genic effect (used to estimate the heritabilities) and ei is
the measurement error. In addition to the same set of
covariates mentioned in Equation (1) we used the differ-
ential gene expression (iFC or oFC, generated in Equa-
tion (2)) as a covariate. We then tested the statistical
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Figure 1 Experimental and analytical protocol used in the study. Experimental series 1 was undertaken to estimate the differential gene
expression in 48,803 probes upon treatment with imatinib or omacetaxine. For these experiments both drugs were administered at a dose of
IC20. Experimental series 2 was undertaken to measure an individual’s sensitivity to drug response (SDR) which was estimated as the slope of the
regression line (arrows) between log of dose administered and cell viability. Data from these experiments were also used to estimate the IC20
values used in Experimental Series 1. Differential gene expression (iFC and oFC) was tested for statistical significance for departure from zero as
well as for association with the corresponding SDR as shown. Details of the statistical methods mentioned in the figure are provided in the text.
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gene expression by constraining this parameter to 0 and
estimating χ2(degree of freedom= 1) as twice the differ-
ence between the log-likelihood estimated from uncon-
strained and constrained models. Simultaneous
associations of the differential gene expression with
iSDR and oSDR for each probe were depicted using bi-
variate 95% confidence ellipses [31]. Between group dif-
ferences were tested using the non-parametric Kruskal-
Wallis test. We used k-means clustering analyses to infer
the potential functional relevance of differentially
expressed genes. For this, we used the Euclidean dis-
tance between pairs of points as the dissimilarity meas-
ure and employed the Stata program Cluster, which uses
the iterative refinement approach for extracting the clus-
ter structure to generate a pre-set number of clusters.
All genetic analyses were conducted using the SOLAR
software package [32] (Version 6.3.7, Texas Biomedical
Research Institute, San Antonio, TX), incorporating an
additional inverse normal transformation on each trait.
Statistical analyses were done using the Stata software
package (Version 12.0, Stata Corp, College Station, TX).All statistical tests were conducted using global type I
error rates of 0.05.
Validation of microarray results by qPCR
To validate results from the Illumina Human WG-6 v3
BeadChips, we performed real-time reverse transcription
polymerase chain reaction (quantitative PCR, qPCR)
analysis on selected transcripts. We utilized HPRT1 as
an endogenous control as our microarray experiments
demonstrated relative stability of gene expression across
all samples when analyzed with NormFinder [33]. Taqman
gene expression assays were obtained from Life Technolo-
gies (Grand Island, NY) for BCL2L10 (Hs00368095_m1),
CTSB (Hs00947433_m1), HPRT1 (Hs99999909_m1),
MUL1 (Hs00226069_m1), OIP5 (Hs00299079_m1) and
TNFAIP3 (Hs00234713_m1). The Illumina probe identi-
fiers that corresponded to these six genes were
ILMN_1749096, ILMN_1696360, ILMN_2056975,
ILMN_1675055, ILMN_1759277, and ILMN_1707591,
respectively. cDNA synthesis was carried out using the
High Capacity cDNA Reverse Transcription Kit with
RNase Inhibitor (Life Technologies), according to the
Table 1 Heritability of the inhibitory concentration of
experimental drugs
Threshold
(%)
Imatinib Omacetaxine
Mean dose
(x10-5 M)
h2 P Mean dose
(x10-8 M)
h2 p
10 1.48 0.60 5.76x10-4 1.04 0.00 0.50
20 3.32 0.60 5.81x10-4 2.35 0.00 0.50
30 5.70 0.60 5.81x10-4 4.03 0.00 0.50
40 8.86 0.60 5.81x104 6.27 0.00 0.50
50 13.29 0.60 5.73x10-4 9.40 0.00 0.50
60 19.03 0.73 1.92x10-5 14.10 0.00 0.50
70 31.00 0.60 5.73x10-4 21.93 0.00 0.50
80 53.14 0.60 5.81x10-4 37.59 0.00 0.50
90 119.60 0.60 5.74x10-4 84.58 0.00 0.50
h2, heritability.
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gene expression assays was carried out in a 10 μl reaction
volume using Gene Expression Master Mix on an Applied
Biosystems 7900HT instrument (Life Technologies),
according to the manufacturers’ instructions. Baseline and
cycle threshold (CT) were determined automatically using
SDS RQ Manager software (Life Technologies). Each sample
was assessed in triplicate and if the CT standard deviation
for triplicate reactions was >0.3 then only duplicate reac-
tions were assessed, if the standard deviation of duplicate
reactions also exceeded 0.3, the sample was excluded
from analysis. Relative quantitation was calculated using
the 2-ΔΔCT method in SDS RQ Manager [34]. To exam-
ine the correlation between microarray and qPCR
results we used Spearman’s or Pearson’s correlation
coefficients, based on the underlying distribution of the
variable. In order to ensure results were directly com-
parable for this association, we corrected the microarray
data for the HPRT1 gene expression.
Results
Assessment of heritability
This study is based on lymphoblastoid cell lines derived
from 55 individuals belonging to 17 pedigrees. The kin-
ships included siblings (72), third degree relations (15)
and an identical sib pair. A total of 48,803 probes, whose
intensities were derived from the microarray experi-
ments, were used for analysis. We first examined the
heritability of the IC values obtained from treatment of
the cell lines with imatinib (n = 109) and omacetaxine
(n = 113). Although both drugs influenced cell viability
in a dose-dependent manner, only the IC values for ima-
tinib demonstrated high heritability (range: 0.60 – 0.73),
IC values for omacetaxine were consistently non-
heritable (Table 1).
Differential gene expression upon treatment
We next examined whether there was a significant dif-
ference in gene expression following treatment with
either imatinib or omacetaxine at an IC20 equivalent
dose. For imatinib, the IC20 values ranged from 8.7×10-6
M to 8.7×10-5 M and for omacetaxine, the IC20 values
ranged from 1.0×10-8 M to 2.2×10-7 M. Volcano plots
(Figure 2A and 2B) indicate numerous statistically sig-
nificant differences in gene expression upon treatment
with both drugs. The mean enrichment score, defined as
the average –log10 p-value, for all 48,803 probes was 0.09
(SD 0.66) after imatinib treatment and 0.46 (SD 1.85) after
omacetaxine treatment; indicating a statistically significant
difference in gene expression induction between imatinib
and omacetaxine treatment (paired Student’s t = 44.886,
degrees of freedom=48,802, tails = 2, p <1x10-22). Following
imatinib treatment, 956 probes (1.96%) demonstrated dif-
ferential gene expression, whilst 3,892 probes (7.97%)showed differential gene expression following omacetaxine
treatment (FDR corrected p-values <0.05). A total of 395 of
these probes (0.8%) were significantly influenced by both
imatinib and omacetaxine treatment. We reduced the
dimensionality of the dataset by using k-means clustering to
generate four non-overlapping clusters, which highlighted
those probes showing differential gene expression following
treatment with imatinib or omacetaxine (Figure 2C).
Probes within cluster 1 (n= 1,378, 30.95%) were mildly
down regulated by imatinib and mildly up regulated by
omacetaxine; those in cluster 2 (n= 2,005, 45.03%) were
down regulated by both imatinib and omacetaxine; those
in cluster 3 (n= 428, 9.61%) were mainly up regulated by
imatinib and those in cluster 4 (n= 642, 14.42%) were
mainly up regulated by omacetaxine. Corroborating these
conceptual inferences, the mean iFC values and the en-
richment scores [mean -log10 (FDR-corrected p-value)]
for probes in the four clusters were −0.02 and 0.35 for
cluster 1; -0.08 and 0.63 for cluster 2; 0.36 and 4.20 for
cluster 3; and 0.13 and 0.67 for cluster 4. The mean oFC
values and enrichment scores for these clusters were 0.26
and 4.31 for cluster 1; -0.35 and 5.05 for cluster 2; 0.10
and 0.89 for cluster 3 and 0.5 and 8.44 for cluster 4.
Functional annotation of identified genes
We next considered whether these unsupervised and un-
biased clusters of probes indicated any underlying func-
tional similarities. First, we used the DAVIDW functional
annotation clustering tool [35,36] to map probes that
showed significant differential gene expression onto
Gene Ontology (GO) terms (Table 2); 83% – 89% of the
significantly identified probes in various clusters were
mapped (overall mapped fraction 85.4%). The full func-
tional annotation of all significant probes is provided in
Additional file 2 for each cluster (see Additional file 2).
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Figure 2 Differential gene expression response upon treatment with imatinib or omacetaxine. (A-B) Volcano plots depicting the extent
(x-axis) and significance (y-axis) of differential gene expression for each probe set (n = 48,803) after treatment with either imatinib (A) or
omacetaxine (B). (C) Results of k-means clustering of the statistically significant probes based on their differential gene expression in response to
imatinib (x-axis) or omacetaxine (y-axis) treatment. The color codes for each cluster are indicated in the index, clusters have been referenced
consistently throughout the manuscript. The lack of data towards the center of the scatter plot is due to probes that were not significant (in
response to either imatinib or omacetaxine treatment), which are not shown in this figure. (D) Point estimates and 95% confidence ellipses for
the association of differential gene expression with sensitivity of drug response (SDR). Plotted in this chart are the regression coefficients from the
polygenic models (equation (2)) for the set of probes belonging to the color-coded clusters identified in panel C. (E) Heritability of differential
gene expression. The data are shown separately for probe sets belonging to each cluster identified in panel C. Pie charts at the top demonstrate
the proportion of probe sets within the corresponding cluster that showed a heritability value exceeding zero for differential gene expression in
response to imatinib as well as omacetaxine. The bar charts show the mean heritability of imatinib (blue) and omacetaxine (red) response for
genes within each cluster. For reference, color-coded background is shown on the chart corresponding to the clusters. Within each cluster, the
difference in the mean heritability for imatinib and omacetaxine response was assessed using a paired Student’s t test, the result of which is
shown as the p-value at the top of the bars. ih2r, heritability of differential gene expression in response to imatinib; oh2r, heritability of differential
gene expression in response to omacetaxine.
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mapped onto the four clusters identified in this study
varied substantially with differing enrichment scores. For
instance, omacetaxine treatment appeared consistent
with reduced cell division and increased apoptosis while
increased kinase binding and vacuole-related functions
were associated with an up regulation in response to
imatinib.
Second, we examined whether each significantly up
regulated probe was associated with iSDR and oSDR.
We found that probes in clusters 1 and 4 did not differfrom each other with respect to their relation with iSDR
and oSDR as indicated by largely overlapping 95% confi-
dence ellipses (Figure 2D). Similarly, the confidence el-
lipses of clusters 2 and 3 overlapped to a large extent.
However, the 95% confidence ellipses of clusters 1 and 4
differed significantly from those of clusters 2 and 3. The
95% confidence ellipses for clusters 1 and 4 (which indi-
cate probes that were significantly up regulated by omace-
taxine but had variable response to imatinib) were more
positively correlated with oSDR than the remaining clus-
ters. Imatinib treatment did not appear to make a
Table 2 Concordance of functional annotation cluster (using DAVIDW) with the four clusters identified based on
differential gene expression
Description Cluster 1 Cluster 2 Cluster 3 Cluster 4
Number of genes
Total 1378 2005 428 642
Identified as human by DAVID 1332 1932 416 617
Mapped by DAVID with
GO terms
1187 (86.1%) 1704 (85.0%) 380 (88.8%) 532 (82.9%)
Functional cluster rank
(enrichment score*)
1 Mitochondria Mitosis Vacuole Anti-apoptosis
(12.08) (24.40) (10.18) (2.72)
2 Ribosomes Kinetochore Endocytosis Kinase binding
(7.72) (16.34) (2.82) (2.67)
3 Catabolism Intracellular organelle Cell fraction Apoptosis regulation
(6.53) (12.53) (2.56) (2.59)
4 Intracellular organelle DNA Replication Metal ion binding Intracellular organelle
(4.80) (11.96) (2.37) (2.25)
5 Ubiquitination DNA Repair Lysosome Metal ion binding
(4.10) (11.85) (1.86) (2.05) and
Tyrosine kinase activity
(2.05)
DAVID Database for Annotation, Visualization and Integrated Discovery; GO gene ontology. enrichment scores are the average –log10 p-values for the genes
loading onto the specified functional cluster.
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In effect, the probes could be clustered into only two
discrete groups based on their regression on to iSDR and
oSDR.
Third, using polygenic models, we found that differ-
ential gene expression in response to imatinib (ih2r)
and omacetaxine (oh2r) for the majority of probes had
measurable (that is exceeded zero) heritability
(Figure 2E). In probes with a measurable heritability,
the estimates of oh2r were significantly higher than
those for ih2r for those probes grouped in clusters 3
(p = 0.05) and 4 (p = 0.03). These observations indicate
that gene response to omacetaxine was more heritable
than gene response to imatinib, especially in clusters 3
and 4.
Previously, we had identified 750 (3.82%) cis-regulated
genes (cis-LOD>3) within a subset of 19,648 transcripts
whose expression was measured in lymphocytes of indi-
viduals within the San Antonio Family Heart Study [29].
Of these cis-regulated transcripts, we identified 41
(5.73%), 57 (5.35%), 8 (3.51%) and 14 (4.42%) that were
present in clusters 1–4, respectively. The number of cis-
regulated transcripts was significantly higher in clusters
1 (χ2 = 6.81, p = 0.009) and 2 (χ2 = 6.54, p = 0.011), as
compared to the overall expected proportion of cis-regu-
lated genes (3.82% as mentioned above). Genes inclusters 3 and 4 did not demonstrate a systematic differ-
ence in the proportion of cis-regulated genes (p = 0.810
and 0.587, respectively). Thus, the genes that were down
regulated by imatinib treatment (clusters 1 and 2) con-
tained a significantly higher proportion of cis-regulated
genes.
Validation of microarray results
We chose five representative genes within the four clusters
identified from the microarray results and conducted
qPCR assays to validate the differential expression of these
genes in response to imatinib and omacetaxine treatment.
Amplification plots for a representative sample for all
five genes are shown in Supplementary Figure 2 (see
Additional file 3). Comparison between the microarray
and qPCR results indicated a statistically significant posi-
tive correlation (Figure 3A), showing that gene expression
results derived from the two assays varied in similar direc-
tions. However, the gene-specific correlations shown in
Supplementary Table 2 (see Additional file 4) demonstrate
variability of correlation across genes. Although not always
significant, the gene expression changes seen between our
qPCR and microarray results were typically correlated. To
better examine whether the two assays demonstrate simi-
lar patterns of gene expression changes, we estimated the
mean differential expression of TNFAIP3, OIP5, MUL1,
-
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goal of replicating the patterns of differential expression.
We found that the direction of change in gene expression
was the same between the two assays for all five genes fol-
lowing omacetaxine treatment, but only 3 of the five genes
following imatinib treatment (Figure 3B); qPCR results for
MUL1 and TNFAIP3 did not corroborate the microarray
results for imatinib treatment. The Pearson’s correlation
coefficient in the mean differential gene expression
estimated by microarray and qPCR was 0.63. Our
qPCR results therefore demonstrate a direction of
effect correlation with the results from microarray
experiments.Differential gene expression and sensitivity of response
We considered the comparative strength of association
of differential gene expression (iFC or oFC) with the
sensitivity of drug response (iSDR or oSDR, respect-
ively). For this we selected all probes which showed a
FDR-corrected statistically significant correlation be-
tween FC and SDR values. We identified 21 genes that
showed a significant association between iFC and iSDR
and 13 genes that showed a significant association be-
tween oFC and oSDR. We annotated these genes using
the GeneGO tool (Table 3). Several interesting candidate
genes, such as STAT1, GPS1, YY1, CYFIP2, and CYP1B1,
PRPF19, KNTC1, GP2 and EDN1, which are known to
partake in important signaling pathways, were identified.
We also found that there was a significant positive cor-
relation between oFC and oSDR (p = 0.004) but not for
iFC and iSDR (Figure 4).Discussion
Our study made three novel and interesting observa-
tions. First, inhibitory concentration values following
treatment with imatinib were highly heritable, although
this was not seen for treatment with omacetaxine. This
finding implies that in a clinical scenario, determination
of a toxic dose of omacetaxine would not need to con-
sider potential familial and heritable influences of drug
cytotoxicity. Second, differential gene expression in re-
sponse to omacetaxine was stronger and more wide-
spread in the genome than for imatinib. Third, the
differential gene expression after omacetaxine exposure
was a significant determinant of an individual’s sensitiv-
ity of drug response (defined as the slope of regression
line between cell viability and log of drug concentration)
but a similar association was not found in the context of
imatinib treatment. Together, this suggests that while
the dose required to induce cell death is not heritable
for omacetaxine, an individual’s sensitivity of genomic
response to a fixed dose of this drug is heritable. In con-
trast, while imatinib toxicity was highly heritable, the ex-
tent of genomic response was more subdued and was
not predictive of the sensitivity of an individual’s re-
sponse to a fixed dose of imatinib. These findings not
only demonstrate the differences between the toxicity
profiles of imatinib and omacetaxine, but also point to-
wards the possibility of successfully using gene-agnostic
drugs as a secondary line of treatment in cases of imati-
nib resistance.
Functional annotation confirmed results from previous
studies that identified kinase binding, apoptosis and
vacuole/lysosome related genes as targets of imatinib
Table 3 Annotation of the 34 genes that were differentially expressed upon treatment as well as associated with SDR
Probe ID Gene symbol Gene name Cluster iFC oFC Pathways
ILMN_1691364 STAT1 Signal transducer and activator
of transcription 1, 91 kDa
1 −0.1071 0.2270 IFNα/ß/Γ; oncostatin M, Thrombopoetin;
Angiopoetin, PDGF; IL-1/IL-9/IL-22;/IL23;
EGFR; p53; SUMO-1; Leptin
ILMN_1700028 C9orf156 Chromosome 9 open reading
frame 156
1 −0.0526 0.2686
ILMN_1747771 MAEA Macrophage erythroblast attacher 1 −0.0370 0.2202
ILMN_1751803 LSM10 LSM10, U7 small nuclear RNA
associated
1 −0.0924 0.1841
ILMN_1770892 YY1 YY1 transcription factor 1 0.0556 0.2401 TGF-ß signaling, NOTCH signaling, p53
signaling
ILMN_2258268 GLRX2 Glutaredoxin 2 1 −0.1088 0.2979
ILMN_2309228 GPS1 G protein pathway suppressor 1 1 0.0364 0.3378
ILMN_1659753 LAMP2 Lysosomal-associated membrane
protein 2
2 0.0400 −0.2695
ILMN_1677691 GP2 Glycoprotein 2 (zymogen granule
membrane)
2 0.0012 −0.3267 Integrin inside-out signaling
ILMN_1682775 EDN1 Endothelin 1 2 −0.5040 −0.4670 Leptin signaling via JAK/STAT & MAPK,
EGFR transactivation, IL-1 signaling,
EDRNA signaling
ILMN_1695058 SLC38A5 Solute carrier family 38, member 5 2 −0.1257 −0.2268
ILMN_1703906 HJURP Holliday junction recognition protein 2 −0.0682 −0.6162
ILMN_1707591 TNIP3 TNFAIP3 interacting protein 3 2 −0.3585 −0.5433
ILMN_1713952 C1orf106 Chromosome 1 open reading frame 106 2 −0.0368 −0.3012
ILMN_1732516 KNTC1 Kinetochore associated 1 2 −0.0216 −0.3534 Spindle assembly
ILMN_1769545 PRPF19 PRP19/PSO4 pre-mRNA processing
factor 19 homolog (S. cerevisiae)
2 −0.0770 −0.3237 NOTCH signaling
ILMN_1774077 GBP2 Guanylate binding protein 2,
interferon-inducible
2 −0.0388 −0.4636
ILMN_1849494 EFR3B EFR3 homolog B (S. cerevisiae) 2 −0.0256 −0.4698
ILMN_1868655 AI916641 2 −0.1451 −0.4635
ILMN_1898692 BI254341 2 −0.2912 −0.3491
ILMN_1912827 CB157495 2 −0.1382 −0.5097
ILMN_2103685 DEPDC1B DEP domain containing 1B 2 −0.1807 −0.7007
ILMN_2230162 FLJ44124 Hypothetical LOC641737 2 0.0233 −0.3135
ILMN_2336595 ACSS2 Acyl-CoA synthetase short-chain
family member 2
2 0.1570 −0.5157
ILMN_2384544 ADAM15 ADAM metallopeptidase domain 15 2 0.2186 −0.3365
ILMN_1677200 CYFIP2 Cytoplasmic FMR1 interacting protein 2 3 0.3287 −0.2998 G-protein signaling RAC1
ILMN_1724437 GCAT Glycine C-acetyltransferase (2-amino-3-
ketobutyrate coenzyme A ligase)
3 0.2763 −0.1991
ILMN_1789436 AK091207 3 0.4950 0.2848
ILMN_2392352 CTPS2 CTP synthase II 3 0.1718 0.0349
ILMN_1664798 GRHPR Glyoxylate reductase/hydroxypyruvate
reductase
4 0.1026 0.4346
ILMN_1693338 CYP1B1 Cytochrome P450, family 1, subfamily B,
polypeptide 1
4 0.1427 0.4242 Benzopyrene, estradiol and retinol
metabolism
ILMN_1764361 DUSP16 Dual specificity phosphatase 16 4 0.2176 0.6187 p53; Erk
ILMN_1779428 C12orf68 Chromosome 12 open reading frame 68 4 0.0770 0.3965
ILMN_1794956 BBS9 Bardet-Biedl syndrome 9 4 0.1743 0.5875
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genome-wide association study in yeast identified the
vacuolar proton transporter ATPase (V-ATPase) protein,
which maintains vacuolar pH, as an important target of
imatinib action [39]. Also, our results indicate that JAK/
STAT, MAPK, Akt, Leptin and NOTCH signaling path-
ways may be perturbed by both imatinib and omacetax-
ine (Table 3), findings that have been observed in
previous studies [40-46]. However, the fact that these
pathways were implicated in the list of the 34 genes
associated with both differential gene expression and
sensitivity to drug response is a novel finding.Limitations
In addition to the limitations implicit in any microarray
study, our study has further limitations. First, this study
was conducted in EBV-transformed lymphoblastoid cell
lines and therefore it should be noted that the differential
gene expression being ascribed to drug treatment are on
the background of an EBV transformation, which may not
truly reflect clinical changes. It is noteworthy that imatinib
can inhibit the virus-specific proliferation of CD8+ T cells
such that there are varying degrees of this inhibitory effect
to peptides derived from cytomegalovirus or EBV [47]. It
has also been reported that one of the manifestations of
imatinib resistance is EBV-positive cutaneous B-cell lym-
phoproliferative disease [48,49]. Given that these cell lines
were all generated in an identical manner, we do not an-
ticipate that all findings within this study would be a con-
sequence of such manifestations. Consistent differential
gene expression changes shown across all cell lines are
likely to represent true gene expression changes, unrelated
to the effect of EBV transformation, however caution
should be taken in the interpretation of these results.Evidence demonstrating an interaction between omace-
taxine and EBV is currently not available.
Second, the microarray studies were conducted by treat-
ing cell lines for 4 days with a preselected concentration
equivalent to the IC20 dose for each drug (to avoid exces-
sive cell death). It is possible that clinical gene expression
changes would be different from those identified in this
study, dependent on the dose chosen and length of treat-
ment. Although our study does not permit interpretation
about dose-related differential gene expression, we dem-
onstrate here, examples of pathways that are likely to be
altered by imatinib or omacetaxine treatment, many of
which have very plausible biological roles in such drug
cytotoxicity.
Third, even though the correlations between results of
qPCR and microarray estimates can be considered to be
modest, these correlations are consistent with those
reported in literature [50]. Indeed, several sources of
variation like degree of differential expression, spot in-
tensity, array averaging and filtering, probe design, bind-
ing sites and variances in amplification methodologies
prevent a direct validation of microarray results by
qPCR. Still, our qPCR results showed moderate con-
cordance with the microarray assay.
We performed this study to gain a better understand-
ing of the effects of imatinib and omacetaxine treatment
on non-cancerous cells in order to identify pathways
that might be consistent with drug cytotoxicity. Our
results can therefore only be interpreted as potential
leads for further research into the cytotoxic effects of
two drugs commonly used to treat CML.Conclusions
We have identified genetic signatures of imatinib and
omacetaxine toxicity in non-cancerous cell lines derived
from closely related individuals. Identification of the
pathways induced by either imatinib or omacetaxine
treatment on non-cancerous cell lines may lead to the
possibility of early detection of subjects who might be
more prone to develop drug cytotoxicity. To our know-
ledge such a microarray study has not been conducted
thus far. Future research should focus on the candidate
genes identified in this study as potential determinants
of drug toxicity in the treatment of CML. Investigation
of such gene expression profiles in CML patients would
be particularly interesting, and may be useful in deter-
mining a cost/benefit ratio of a treatment regime.Additional files
Additional file 1: Figure S1. Quantile normalization of gene expression
data.
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Additional file 3: Figure S3. Representative amplification plots from
RT-PCR for selected genes.
Additional file 4: Table S2. Gene-specific correlation between the
results of q-PCR and microarray.
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